Kymera Therapeutics Inc’s recent filing unveils that its Director Ridloff Elena unloaded Company’s shares for reported $0.23 million on Jun 11 ’25. In the deal valued at $50.00 per share,4,500 shares were sold. As a result of this transaction, Ridloff Elena now holds 0 shares worth roughly $0.0.
Then, ELENA RIDLOFF bought 4,500 shares, generating $218,700 in total proceeds.
Before that, Esposito Pamela sold 5,000 shares. Kymera Therapeutics Inc shares valued at $245,186 were divested by the Director at a price of $49.04 per share. As a result of the transaction, Esposito Pamela now holds 0 shares, worth roughly $0.0.
Morgan Stanley upgraded its Kymera Therapeutics Inc [KYMR] rating to an Overweight from a an Equal-weight in a research note published recently. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who increased its forecast for the stock in early June from “a Neutral” to “a Buy”. BofA Securities also remained covering KYMR and has increased its forecast on June 02, 2025 with a “Buy” recommendation from previously “Neutral” rating.
Price Performance Review of KYMR
On Tuesday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock jump 1.84% to $47.14. Over the last five days, the stock has gained 0.64%. Kymera Therapeutics Inc shares have risen nearly 50.75% since the year began. Nevertheless, the stocks have risen 17.18% over the past one year. While a 52-week high of $53.27 was reached on 06/11/25, a 52-week low of $19.44 was recorded on 04/09/25.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 46.11, which if violated will result in even more drops to 45.07. On the upside, there is a resistance level at 47.95. A further resistance level may holdings at 48.76.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-05-30, dropping by -0.6 million shares to a total of 6.59 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 7.18 million shares. There was a decline of -9.06%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 13, 2025 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $52 price target.
